A point-prevalence study for MRSA in a German university hospital to identify patients at risk and to evaluate an established admission screening procedure.

Infection
Iris F ChabernyPetra Gastmeier

Abstract

Due to the enormous increase in the number of MRSA-patients, in July 2004, an extended admission screening protocol was implemented in ICUs and surgical wards at Hannover Medical School. In 2005, a point-prevalence study (also known as a cross-sectional study) was conducted to determine the prevalence of MRSA and Panton-Valentine leukocidin (PVL) among inpatients, to identify patients at risk for MRSA colonization and to evaluate compliance with admission screening. Inpatients were screened by taking cultures from nose, throat and skin lesions. S. aureus isolates were tested for antimicrobial susceptibility and PVL. MRSA was analyzed by staphylococcal protein A (spa) typing. Of 509 inpatients, 145 (28%) were S. aureus carriers. 27 (19%) inpatients were MRSA positive, i.e., the MRSA point-prevalence was 5.3% (95% CI, 3.49; 7.70). spa type t032 was predominant in 67% of the MRSA inpatients. The PVL gene was present in one (0.2%) methicillin-susceptible strain. Comparison with data retrieved from the local hospital MRSA database showed that, the status of 37% of the MRSA had previously remained undetected (10/27). Consequently, MRSA colonization was newly identified in 2.0% (10/509) of the patients. Compliance with admission scree...Continue Reading

Citations

Mar 5, 2011·Der Unfallchirurg·I F Chaberny, K Graf
May 11, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TübbickeS Fleßa
Feb 9, 2012·Epidemiology and Infection·B BisdorffK Radon
May 24, 2011·BMC Infectious Diseases·Madeleine DulonAlbert Nienhaus
Mar 5, 2009·Future Microbiology·Susanne Nylén, Hannah Akuffo
Sep 11, 2013·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·James A McKinnellSusan S Huang
May 29, 2020·Biomédica : revista del Instituto Nacional de Salud·Heidy C Martínez-DíazMarylin Hidalgo
Dec 14, 2011·Deutsches Ärzteblatt International·Robin KöckKarsten Becker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.